Want to see TVRD full AI Analyst Report?
TVRD Stock Chart & Stats
$3.39
--
Market closed
$3.39
--
Day’s Range― - ―
52-Week Range$1.50 - $43.65
Previous CloseN/A
VolumeN/A
Average Volume (3M)3.93M
Market Cap
$35.65M
Enterprise Value$4.53M
Total Cash (Recent Filing)$24.98M
Total Debt (Recent Filing)$174.00K
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Aug 13, 2026EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.59
Shares Outstanding9,381,344
10 Day Avg. Volume11,662,801
30 Day Avg. Volume3,928,707
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-1.36
Enterprise Value/Market Cap0.13
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-96.32
Enterprise Value/Ebitda-0.30
Forecast
1Y Price Target
$10.29Price Target Upside203.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.54
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Proof-of-MechanismPhase 1 pharmacodynamic and PK signals for TTI-109 demonstrate durable target engagement and an improved tolerability profile versus prior molecule. That provides a credible path to Phase 2 programs in dermatology and GI disease, supporting long-term clinical differentiation and partner interest.
Low Leverage / Improved Balance SheetA materially reduced debt load and equity recovery after recent financing improve solvency and strategic optionality. For a clinical-stage biotech, lower leverage reduces near-term default risk and makes it easier to secure partner deals or bridge financings to fund pivotal development over the coming 2–6 months.
Strengthened Corporate GovernanceRecent shareholder approvals and conventional governance moves (board slate, auditor ratification, say-on-pay alignment) signal institutional oversight and alignment with investors. Strong governance supports credibility with potential partners and investors during fundraisings and long-term program execution.
Bears Say
Zero Revenue & Heavy Cash BurnThe company currently reports no commercial revenue while burning substantial cash annually. Persistent negative operating cash flow forces recurrent external financing, increasing dilution risk and creating a structural constraint on sustaining multi-arm development without new capital or partner deals.
Sustained Operating LossesHistoric revenue decline to zero and ongoing operating losses mean TVRD lacks internal profitability or self-funding capacity. This structural lack of earnings reduces strategic flexibility, pressures R&D prioritization, and heightens reliance on milestone-dependent financing or licensing arrangements.
Regulatory & Financing Gate For Phase 2Progress to pivotal Phase 2 is explicitly conditional on IND clearance and new funding, creating two durable gating risks. Regulatory delay or failure and inability to raise capital would materially delay development timelines and weaken negotiating leverage with partners or acquirers.
Tvardi Therapeutics News
TVRD FAQ
What was Tvardi Therapeutics Inc.’s price range in the past 12 months?
Tvardi Therapeutics Inc. lowest stock price was $1.50 and its highest was $43.65 in the past 12 months.
What is Tvardi Therapeutics Inc.’s market cap?
Tvardi Therapeutics Inc.’s market cap is $35.65M.
When is Tvardi Therapeutics Inc.’s upcoming earnings report date?
Tvardi Therapeutics Inc.’s upcoming earnings report date is Aug 13, 2026 which is in 33 days.
How were Tvardi Therapeutics Inc.’s earnings last quarter?
Currently, no data Available
Is Tvardi Therapeutics Inc. overvalued?
According to Wall Street analysts Tvardi Therapeutics Inc.’s price is currently Undervalued.
Does Tvardi Therapeutics Inc. pay dividends?
Tvardi Therapeutics Inc. does not currently pay dividends.
What is Tvardi Therapeutics Inc.’s EPS estimate?
Tvardi Therapeutics Inc.’s EPS estimate is -0.7.
How many shares outstanding does Tvardi Therapeutics Inc. have?
Tvardi Therapeutics Inc. has 9,381,344 shares outstanding.
What happened to Tvardi Therapeutics Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tvardi Therapeutics Inc.?
Currently, no hedge funds are holding shares in TVRD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tvardi Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.29 (203.41% Upside)
$10.29 (203.41% Upside)
Blogger Sentiment
Bullish
TVRD Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 21.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.1%
Last 30 Days ▲ 2.9%
Last 30 Days ▲ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.82%
12-Months-Change
Fundamentals
Return on Equity
-64.17%
Trailing 12-Months
Asset Growth
-33.71%
Trailing 12-Months
Company Description
Tvardi Therapeutics Inc.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
TVRD Stock 12 Month Forecast
Average Price Target
$10.29
▲(203.41% Upside)
Technical Analysis
Plus Therapeutics
―
Cue Biopharma
―
Aligos Therapeutics
―
Genenta Science SpA Sponsored ADR
―
Adlai Nortye Ltd. Sponsored ADR
―
Ownership Overview
8.15% Insiders
7.98% Mutual Funds
11.87% Other Institutional Investors
67.96% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---